SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
申请人:Eastwood Paul Robert
公开号:US20110053936A1
公开(公告)日:2011-03-03
The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Optimisation of a series of indolin-2-one p38 alpha inhibitors was achieved via both blocking of a potential metabolic 'hot spot' and by increasing overall polarity of the lead series leading to non-cytotoxic compounds which showed improved oral bioavailabilities in the rat. (C) 2011 Elsevier Ltd. All rights reserved.
NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
申请人:Almirall, S.A.
公开号:EP2280943B1
公开(公告)日:2013-11-06
US8772288B2
申请人:——
公开号:US8772288B2
公开(公告)日:2014-07-08
[EN] NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS.<br/>[FR] NOUVEAUX DÉRIVÉS SUBSTITUÉS DE SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA KINASE ACTIVÉE PAR LE MITOGÈNE P38
申请人:ALMIRALL SA
公开号:WO2009124692A1
公开(公告)日:2009-10-15
This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.